Sign in
Taking peoplePhase 4

Intravenous iron for anemia after heart surgery in older adults

Tests iron given through a vein for anemia after heart surgery in older patients.

Key facts

Who runs it
dr. P. Noordzij
Where
Netherlands4 sites in 1 countryChoose a country to see its sites
Registry title
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
Status
Recruiting
Phase
Phase 4
People taking part
310 people, planned
Started
23 Sept 2021
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ferric Derisomaltose 100 MG/ML
  • Sodium chloride
Record updated
27 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 70 or older with low blood and low iron after planned heart valve (AVR) or bypass (CABG) surgery. They get either intravenous iron or a placebo.

Age
70 years and older
Sex
All sexes
Disease stage
Moderate iron deficiency anemia after planned AVR or CABG surgery. Recovery must be expected to go smoothly: no heart-support drugs or breathing machine on the first day after surgery, and a move to the general ward expected that day.
Earlier treatment
Planned AVR or CABG heart surgery. No intravenous iron (IVI) in the 12 weeks before.
Biomarker or test result
Hb between 85 and 110 g/L, and ferritin <100 µg/L or iron saturation (TSAT) < 20%.

Main reasons for not taking part

  • Past iron overload or haemochromatosis
  • Liver cirrhosis, or ALT/AST three times the normal value (women: ALT >120, AST >105 U/L; men: ALT>150, AST>135 U/L)
  • Severe kidney failure (eGFR<15ml/min/1.73m2)
  • Past serious allergic reaction to intravenous iron
  • Past severe asthma or eczema

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Mentally competent with age ≥ 70 years
  • Elective AVR or CABG surgery
  • Expected uncomplicated postoperative trajectory, defined as:
  • No inotropic agents or ventilation at time of final inclusion (POD 1)
  • Expected discharge to general ward at POD 1
  • Moderate postoperative IDA, defined as:
  • Hb between 85 and 110 g/L and
  • Ferritin <100 µg/L or
  • Iron saturation (TSAT) < 20%

Who cannot take part

  • Recent treatment with IVI (<12 weeks prior)
  • Medical history of iron overload/haemochromatosis
  • Serious or severe allergic reaction to IVI in medical history
  • Medical history of liver cirrhosis or ALT/AST value in blood serum triple of normal value (female patients: ALT >120, AST >105 U/L. Male patients: ALT>150, AST>135 U/L)
  • Severe renal failure (eGFR<15ml/min/1.73m2)
  • Severe asthma or eczema in medical history (atopic constitution)

This trial is currently available in Netherlands.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Postoperative anemia is common in cardiac surgery with cardiopulmonary bypass. Iron deficiency delays the recovery from postoperative anemia and may negatively affect the postoperative trajectory of cardiac surgery patients. The objective of the study is to determine the effect of treatment of postoperative iron deficiency anemia with intravenous iron on disability 90 days after surgery. This will be evaluated in a randomized placebo-controlled double blind two-center trial in which 310 elective cardiac surgery patients will be included.

The 2 groups in the trial

  • Intravenous iron (ferric derisomaltose)Treatment being tested

    The intervention consists of a single dose of ferric derisomaltose (Monofer®) 100 mg/mL solution for infusion (Monofer® is a registered product with a marketing authorization in the Netherlands (RVG number: 103070). Manufacturer: Pharmacosmos A/S, Denmark. Dutch marketing authorization holder: Cablon Medical B.V). The method of administration and dosage of the investigational medication are standard treatment. The ferric derisomaltose dose will calculated for each patient depending on body weight (20mg/kg) and diluted in 250 ml NaCl 0.9%. Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards

    Treatment: Ferric Derisomaltose 100 MG/ML

  • PlaceboPlacebo, for comparison

    Single dose of sodium chloride 0.9% (250ml). Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards

    Treatment: Sodium chloride

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients: a Randomized Controlled Trial'
Plain-language title
Intravenous iron for anemia after heart surgery in older adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Publications
Record updated
27 April 2026